272 related articles for article (PubMed ID: 18955086)
1. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
[TBL] [Abstract][Full Text] [Related]
3. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
[TBL] [Abstract][Full Text] [Related]
4. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.
Alaghehbandan R; Fontaine D; Bentley J; Escott N; Ghatage P; Lear A; Coutlee F; Ratnam S
Diagn Cytopathol; 2013 Sep; 41(9):767-75. PubMed ID: 23341349
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
Baasland I; Romundstad PR; Eide ML; Jonassen CM
PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.
Cattani P; Zannoni GF; Ricci C; D'Onghia S; Trivellizzi IN; Di Franco A; Vellone VG; Durante M; Fadda G; Scambia G; Capelli G; De Vincenzo R
J Clin Microbiol; 2009 Dec; 47(12):3895-901. PubMed ID: 19828739
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients.
Benevolo M; Terrenato I; Mottolese M; Marandino F; Carosi M; Rollo F; Ronchetti L; Muti P; Mariani L; Sindico S; Vocaturo G; Vocaturo A
Cancer Causes Control; 2011 Jun; 22(6):869-75. PubMed ID: 21424209
[TBL] [Abstract][Full Text] [Related]
8. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
[TBL] [Abstract][Full Text] [Related]
9. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.
Tropé A; Sjøborg K; Eskild A; Cuschieri K; Eriksen T; Thoresen S; Steinbakk M; Laurak V; Jonassen CM; Westerhagen U; Jacobsen MB; Lie AK
J Clin Microbiol; 2009 Aug; 47(8):2458-64. PubMed ID: 19535524
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
[TBL] [Abstract][Full Text] [Related]
11. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.
Varnai AD; Bollmann M; Bankfalvi A; Speich N; Schmitt C; Griefingholt H; Kovács K; Klozoris C; Bollmann R
Oncol Rep; 2008 Feb; 19(2):457-65. PubMed ID: 18202795
[TBL] [Abstract][Full Text] [Related]
12. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
[TBL] [Abstract][Full Text] [Related]
13. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
14. Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a.
Andersson S; Hansson B; Norman I; Gaberi V; Mints M; Hjerpe A; Karlsen F; Johansson B
Int J Oncol; 2006 Sep; 29(3):705-11. PubMed ID: 16865288
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.
Perez Castro S; Iñarrea Fernández A; Lamas González MJ; Sarán Diez MT; Cid Lama A; Alvarez Martín MJ; Pato Mosquera M; López-Miragaya I; Estévez N; Torres Piñón J; Oña Navarro M
J Med Virol; 2013 Jun; 85(6):1063-8. PubMed ID: 23588733
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
17. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses.
Molden T; Kraus I; Skomedal H; Nordstrøm T; Karlsen F
J Virol Methods; 2007 Jun; 142(1-2):204-12. PubMed ID: 17379322
[TBL] [Abstract][Full Text] [Related]
18. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
Persson M; Brismar Wendel S; Ljungblad L; Johansson B; Weiderpass E; Andersson S
Oncol Rep; 2012 Jul; 28(1):346-52. PubMed ID: 22484610
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus DNA and E6/E7 mRNA testing as triage in liquid-based cytology samples from primary screening.
Andersson S; Mints M; Weiderpass E; Johansson B
Curr Pharm Des; 2013; 19(8):1508-15. PubMed ID: 23072430
[TBL] [Abstract][Full Text] [Related]
20. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
